Skip to content
Drug Pipeline

Lilly–Hims & Hers Deal: Zepbound From $299 and Foundayo From $149 on the Platform

4 min readBy Jeremy H., GLP-1 Nutrition Researcher
Lilly–Hims & Hers Deal: Zepbound From $299 and Foundayo From $149 on the Platform

On November 6, 2026, Eli Lilly and Hims & Hers Health announced an agreement that gives eligible patients on the Hims & Hers telehealth platform access to Zepbound (tirzepatide) and Foundayo (orforglipron) at Lilly's self-pay prices. Patients complete a consultation, receive a prescription if a licensed provider determines it is appropriate, and have the medicine shipped to their home, without leaving the Hims & Hers platform.

Key Points

  • Agreement date: November 6, 2026, announced jointly by Eli Lilly and Hims & Hers Health.
  • Self-pay prices: Foundayo starts at $149 per month and Zepbound starts at $299 per month, matching the self-pay prices available through LillyDirect.
  • Compounded copies: Hims & Hers has never offered compounded copies of Lilly's GLP-1 medicines and has committed not to do so in the future.
  • Price deadline: The reduced Foundayo prices of $149 at 2.5 mg and $199 at 5.5 mg run through December 31, 2026.

What the agreement changes

Before the agreement, Hims & Hers patients who were prescribed a Lilly medicine were routed to LillyDirect, Lilly's direct-to-consumer channel, to complete the purchase. The agreement moves that step inside the Hims & Hers platform, so the consultation, prescription, and delivery happen in one place.

The change is about the route to the medicine, not the medicine itself. Zepbound and Foundayo are the same FDA-approved Lilly products, and the prices are the same self-pay prices Lilly charges any cash-paying patient. A prescription from a licensed provider is still required, and the release states that providers on the platform will continue to prescribe the treatment they determine is right for each patient.

Hims & Hers already offers Novo Nordisk medicines on its platform under a separate collaboration announced in March 2026. With this agreement, the platform now carries FDA-approved GLP-1 medicines from both Lilly and Novo Nordisk.

Prices: what $149 and $299 cover

Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound, according to the joint announcement. The words "starts at" matter. Higher doses cost more, and the release gives only the starting prices.

LillyDirect's self-pay price list, checked November 2026, sets Foundayo at $149 a month at 0.8 mg and 2.5 mg, $199 at 5.5 mg, and $299 from 9 mg. Zepbound self-pay starts at $299 a month at the lowest dose, with higher doses priced above that. Prices are for the medication only. The release describes a weight-loss membership with 24/7 care-team access, nutrition guidance, and regular check-ins, but it does not give a price for that membership, so the figures above are not an all-in cost.

The weekly GLP-1 email

Plain-English answers on side effects, eating, cost and the newest medications. Free, one email a week.

The December 31, 2026 price deadline

Two Foundayo steps are temporarily reduced on LillyDirect, and the reduction ends December 31, 2026. The 2.5 mg dose is reduced from $199 to $149, and the 5.5 mg dose is reduced from $299 to $199. After December 31, 2026, those doses return to their regular prices of $199 and $299. Because the Hims & Hers prices match Lilly's self-pay prices, the same deadline applies to the prices quoted through the platform.

The commitment on compounded copies

The joint announcement states that Hims & Hers has never offered access to compounded copies of Lilly's GLP-1 medicines and has committed not to do so in the future. The companies also committed to protecting independent clinical decision-making by providers on the platform.

What is still unknown

The announcement gave no go-live date for the integrated ordering, so availability on the platform may vary by patient. The release also says nothing about insurance coverage for these medicines through Hims & Hers. The prices in this article are self-pay prices, checked November 2026, and they can change.

Sources: Eli Lilly and Hims & Hers joint announcement, November 6, 2026; Pharmacy Times, November 10, 2026; Foundayo self-pay prices and December 31, 2026 reduction end date, LillyDirect Foundayo self-pay pricing, checked November 2026.

The weekly GLP-1 email

Plain-English answers on side effects, eating, cost and the newest medications. Free, one email a week.

We respect your privacy. Unsubscribe anytime.

Next up

A few related reads to keep your momentum.

Related articles

Written by
J
Jeremy H.
GLP-1 Nutrition Researcher

Nutrition researcher and founder of The GLPSpot. Jeremy built this site after watching friends and family struggle with the nutritional challenges of reduced appetite on GLP-1 medications — loss of muscle mass, dehydration, and nutrient deficiencies.

Published:
Medical Disclaimer: This content is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment.